|
Synonyms: (-)-oxybutynin | (r)-oxybutynin | (R)OXY [3]
Compound class:
Synthetic organic
Comment: Aroxybutynin is the R-enantiomer of racemic oxybutynin. It is reported as the enantiomer that is predominantly responsible for the antimuscarinic effect of oxybutynin [3].
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Horner RL, Wellman DA, Sands SA, Azarbarzin A, Taranto-Montemurro L. (2026)
Mechanisms of upper airway muscle control in sleep reveal therapeutic targets for obstructive sleep apnea. Am J Respir Cell Mol Biol, 74 (7): 847-857. [PMID:42148507] |
|
2. Mehra R, Mokhlesi B. (2026)
Mechanism-directed pharmacotherapy in obstructive sleep apnea: insights from aroxybutynin/atomoxetine (AD109) intervention in the SynAIRgy trial. Am J Respir Crit Care Med, 212 (7): 1427-1429. [PMID:42148681] |
|
3. Noronha-Blob L, Kachur JF. (1991)
Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther, 256 (2): 562-7. [PMID:1993995] |
|
4. Rosenberg R, Abaluck B, Thein S. (2022)
Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA. J Clin Sleep Med, 18 (12): 2837-2844. [PMID:35975547] |
|
5. Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, Rosenberg R, Corser B, Abaluck B, Sangal RB, Maynard J. (2023)
The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial. Am J Respir Crit Care Med, 208 (12): 1316-1327. [PMID:37812772] |
|
6. Strollo Jr PJ, Farkas R, Taranto-Montemurro L, Cronin J, Patel SR, SynAIRgy Investigators. (2026)
Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy). Am J Respir Crit Care Med, 212 (7): 1569-1584. [PMID:42148495] |
|
7. Taranto-Montemurro L, Patel SR, Strollo Jr PJ, Cronin J, Yee J, Pho H, Werner A, Farkas R. (2025)
Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials. Contemp Clin Trials Commun, 47: 101538. [PMID:41050845] |